Clinical bottom line
Rare inherited autoinflammatory interferonopathies represent a distinct group of monogenic disorders characterized by dysregulated type I interferon signaling, leading to systemic inflammation and multi-organ involvement. Clinical recognition remains challenging due to phenotypic overlap with other autoinflammatory and autoimmune diseases. Current evidence supports the use of targeted JAK inhibitors as a promising therapeutic approach, although long-term safety and efficacy data are limited. Early genetic diagnosis coupled with tailored immunomodulatory treatment may improve outcomes, but management requires multidisciplinary expertise and individualized care plans.
What the evidence shows
Inherited autoinflammatory interferonopathies are caused by mutations in genes regulating nucleic acid metabolism or sensing, resulting in chronic activation of type I interferon pathways (Ferguson et al., 2020; Lin et al., 2022). These disorders include conditions such as Aicardi-Goutières syndrome, STING-associated vasculopathy with onset in infancy (SAVI), and CANDLE syndrome, each presenting with overlapping features of systemic inflammation, vasculopathy, and organ-specific damage (Savic et al., 2022; Shalala et al., 2017).
Clinical manifestations often include recurrent fevers, skin rashes, arthritis, interstitial lung disease, and neurological impairment. Laboratory findings typically show elevated interferon-stimulated gene expression and inflammatory markers (Melki et al., 2020). Diagnosis relies on a combination of clinical suspicion, genetic testing, and biomarker assessment (Davidson et al., 2018).
Therapeutically, JAK inhibitors such as baricitinib and ruxolitinib have demonstrated efficacy in reducing interferon-driven inflammation by blocking downstream signaling pathways (Lin et al., 2022; Savic et al., 2022). Case series and small cohort studies report improvements in systemic symptoms, skin lesions, and pulmonary function, although randomized controlled trials are lacking. Conventional immunosuppressants often provide limited benefit and carry risks of infection (Ferguson et al., 2020).
The COVID-19 pandemic has highlighted additional challenges in managing these patients, who may be at increased risk of severe infection and require careful balancing of immunosuppression (Tobór-Świętek et al., 2021). Multidisciplinary care involving rheumatology, immunology, pulmonology, and genetics is essential for optimal management (Melki et al., 2020).
Caveats and uncertainty
The rarity and heterogeneity of inherited interferonopathies limit large-scale clinical trials, resulting in reliance on case reports and small cohorts. The long-term safety profile of JAK inhibitors in pediatric and adult populations with these disorders remains incompletely characterized (Lin et al., 2022). Biomarkers for disease activity and treatment response are evolving but not yet standardized (Davidson et al., 2018).
Genetic testing panels vary in coverage, and some pathogenic variants may be missed, complicating diagnosis. Phenotypic overlap with other autoinflammatory or autoimmune diseases can delay recognition and appropriate therapy (Ferguson et al., 2020). The impact of early versus late intervention on disease progression is not well defined.
Furthermore, the balance between immunosuppression and infection risk, especially in the context of emerging infectious threats such as SARS-CoV-2, requires ongoing vigilance and individualized risk assessment (Tobór-Świętek et al., 2021).
How this may change practice
Clinicians should maintain a high index of suspicion for inherited interferonopathies in patients with early-onset systemic inflammation, vasculopathy, and unexplained organ dysfunction. Integration of rapid genetic testing and interferon signature assays into diagnostic workflows can facilitate earlier diagnosis and targeted treatment initiation.
The emerging evidence supporting JAK inhibitors encourages their consideration as first-line targeted therapy, particularly in refractory cases or those with significant organ involvement. Multidisciplinary collaboration is critical to optimize immunomodulation while minimizing adverse effects.
Ongoing research and clinical registries will be essential to refine treatment protocols, identify biomarkers predictive of response, and establish long-term safety profiles. Awareness of infectious risks and vaccination strategies should be incorporated into care plans.